An interventional study of Dexmedetomidine 0.5 ug/kg and Dexmedetomidine 0.75 mcg/kg in Fracture Femur, Dexmedetomidine Analgesia and Fascia Iliaca Block, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
### Brief Summary
Femoral fractures can cause severe pain during and after surgery. Although fascia iliaca block is commonly used to relieve pain in patients undergoing femoral fracture surgery, the duration of pain relief may be limited.
Dexmedetomidine is a medication that may prolong the pain-relieving effect of local anesthetics such as bupivacaine. However, the most appropriate dose of dexmedetomidine for this type of nerve block is not yet clearly established.
This study aims to determine the lowest effective dose of dexmedetomidine when added to bupivacaine for ultrasound-guided fascia iliaca block in patients undergoing femoral fracture surgery under general anesthesia.
The study includes 90 adult patients, aged 18-75 years, who are scheduled for femoral fracture surgery. Participants will be randomly assigned to one of three groups, with 30 patients in each group. All patients will receive general anesthesia and an ultrasound-guided fascia iliaca block containing 30 mL of 0.25% bupivacaine, combined with one of the following doses of dexmedetomidine:
Neither the patients nor the doctors assessing the study outcomes will know which dose has been administered.
Pain levels will be assessed during the first 24 hours after surgery using a numerical pain scale. The study will also measure the time until patients first require additional pain medication and the total amount of pain medication used.
Other assessments will include leg muscle strength, level of sedation, heart rate, blood pressure, and any possible side effects or complications.
The main purpose of this study is to identify the lowest dose of dexmedetomidine that provides effective postoperative pain relief while minimizing unwanted effects, helping improve pain management and recovery after femoral fracture surgery.
188 studies on the registry are indexed under Femoral Fractures; 40 are open to participants now.
This study's planned enrollment of 90 is above the median of 63 across 116 interventional studies indexed under Femoral Fractures.
Browse Femoral Fractures studies →Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age between 18-75 years. both sexes. (ASA) physical status I-III Scheduled for femoral fracture surgery
Exclusion Criteria:
Allergy to study drugs. Heart block type II. Pre-existing neurologic or psychiatric disease. Severe hepatic or renal impairment. Infection at injection site.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Name: Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia
Drug: Dexmedetomidine 0.5 ug/kg
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.
Drug: Dexmedetomidine 0.75 mcg/kg
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesi
Drug: Dexmedetomidine 1 mcg/kg
Drug page: DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Intervention 1 - Group dexmeditomidine 0.5 Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. \---
Also known as: bupivacaine
Drug page: DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.
Drug page: DexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia.
Time to the first request for rescue analgesia in minutes
time in minutes to first rescue analgesia will be measured.
Time frame: from end of surgery to the first request for nalbuphine
postoperative pain assessed as Numerical rating score (NRS)
Time frame: from 30 minutes after surgery to 24 hours after surgery
motor block using modified bromage scale
Time frame: from 30 minutes to 24 hours after surgery
total nalbuphine consumption in milligram (mg)
Time frame: from end of surgery to 24 hours after surgery
heart rate
Time frame: starting before general anesthesia till 60 minutes after surgery
sedation score
using ramsay sedation scale
Time frame: from 30 minutes after the end of operations to 24 hours postoperative .
mean arterial pressure
Time frame: starting before general anesthesia till 60 minutes after surgery
systolic blood pressure
Time frame: starting before general anesthesia till 60 minutes after surgery
diastolic blood pressure
Time frame: starting before general anesthesia till 60 minutes after surgery
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.
Of 50 non-industry interventional studies with no phase under Femoral Fractures, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 50. This study's planned 3 months is below that.
Counting every sponsor, half of 53 studies reached it within 23 months; a quarter within 9 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine